pharma · Hepatitis C Virus Infection · Chronic Hepatitis B
Gilead Sciences Ireland
Gilead Sciences Ireland UC
Gilead Sciences Ireland clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 333 Lakeside Drive, Foster City, CA 94404, US
- Founded
- 1987
- Employees
- 14,602
- Programs
- 26
- Drugs
- 17
- Patents
- 0
Gilead Sciences Ireland projects
6 ClinicalTrials.gov programs sponsored by Gilead Sciences Ireland.
Gilead Sciences Ireland has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
B/F/TAF
Gilead Sciences Ireland UC
HIV-1-infection
1 trial -
Evixapodlin
Gilead Sciences Ireland UC
Advanced Solid Tumors
1 trial -
GS-0272
Gilead Sciences Ireland UC
Rheumatoid Arthritis
1 trial -
GS-2829
Gilead Sciences Ireland UC
Chronic Hepatitis B
1 trial -
Lanraplenib.
Gilead Sciences Ireland UC
Inflammatory Disease
1 trial -
SOF/VEL/VOX
Gilead Sciences Ireland UC
HCV Infection
1 trial
Frequently asked questions
How many clinical projects does Gilead Sciences Ireland have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.